Janssen Pharmaceutical Companies Launch Healthy Minds Initiative

Healthy Minds Brings Together Researchers and Data to Solve Mysteries of the Brain, Commits Key Research Programs to Public Sector, and Addresses Stigma

Healthy Minds Brings Together Researchers and Data to Solve Mysteries of the Brain, Commits Key Research Programs to Public Sector, and Addresses Stigma

Titusville, NJ, November 10, 2011 /PRNewswire/

Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”) today announced the launch of Healthy Minds, a comprehensive initiative to accelerate progress in the fight against brain disorders that affect millions of people around the world.  Healthy Minds includes a significant new commitment by Janssen Pharmaceuticals, Inc. of $3 million in direct and challenge contributions to the International Mental Health Research Organization (IMHRO) (www.imhro.org), to support One Mind for Research (1mind4research.org), a program of IMHRO that fosters neuroscience research, education, and awareness-building programs.

As part of the Healthy Minds efforts, Janssen will become the first private-sector partner to support the One Mind for Research program, which was started by former U.S. Congressman Patrick Kennedy and Garen Staglin, Vice President, Board of Directors, IMHRO.  Janssen will contribute $2 million in cash to IMHRO for the One Mind for Research program and $1 million in matching funds for donations raised by IMHRO for the One Mind for Research program from other private-sector partners.  Janssen plans to participate in the program’s efforts to create collaborative neuroscience networks and data-sharing programs that enhance basic discovery and speed clinical translation.

Janssen plans to work with One Mind for Research to develop research programs, expand data sharing among scientists and physicians focused on the brain or central nervous system, break down barriers to understanding the molecular and cellular origins of mental and neurologic disorders, and help combat the stigma faced by those affected by brain diseases.
The goal of One Mind for Research is to help to de-stigmatize mental-health conditions and improve understanding of their molecular and cellular origins.  IMHRO is a nonprofit organization that seeks to improve the health and functioning of people who suffer from brain or central nervous system disorders.  Healthy Minds also aims to encourage collaboration among biotechnology, pharmaceutical, and public-sector partners to accelerate the discovery of new therapeutic solutions for brain disease.

“Brain disorders are one of the most challenging areas of scientific research,” said Sheri McCoy, Vice Chairman, Executive Committee, Johnson & Johnson.  “Despite great progress in advancing new treatments, the brain remains a medical mystery and millions of people continue to suffer from Alzheimer’s disease, depression, post traumatic stress disorder, neurologic conditions, and many other debilitating and life threatening brain diseases.”

“Rapid advances in science and technology over the past decade provide us with an unprecedented opportunity and the tools needed to unlock the secrets of the brain, but the challenge is too great and the data too vast for any one entity to do it alone,” said Husseini K. Manji, M.D., Global Therapeutic Area Head for Neuroscience, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.  “A concerted and focused effort, including public-private partnerships, is needed to foster the development of new, transformational medicines and treatment paradigms.  Building on our heritage and capabilities in neuroscience and our culture of networked innovation, we are proud of the Healthy Minds initiative.  We are pleased to support the One Mind for Research efforts to get to the next frontier of neuroscience and support improved health of millions of people who suffer from brain disorders.”
The Healthy Minds initiative builds on Janssen’s longstanding legacy of achievement in advancing neuroscience research.  The company’s work in this area dates back to the 1950s and the discovery and development by Dr. Paul Janssen of one of the first breakthrough treatments for schizophrenia.  Paul Janssen is known as one of the 20th century's most gifted and passionate physicians and pharmaceutical researchers and is the namesake of Janssen Pharmaceuticals, Inc.  Since then, Janssen has discovered, developed, and launched many innovative treatments for brain and central nervous system conditions and remained firmly committed to neuroscience.  Janssen commits more than $12 million annually to public and professional education about mental illness and brain disorders, and sponsorships and philanthropy in the field of neuroscience and mental health.  Janssen’s contribution to IMHRO is confirmation of Janssen’s continued commitment in neuroscience research and development.

“Janssen is leading the way with its partnerships in developing scientific and public health solutions in the fight against brain disorders,” said former U.S. Congressman Patrick Kennedy.  “We are pleased to welcome them as a key private-sector partner in driving forward important R&D and awareness-building initiatives.  This support will lead to a fundamental understanding of the human brain, what causes brain disorders, and how they can be treated and cured.”

"As a family member of someone living with schizoaffective disorder, I am proud to support IMHRO’s profoundly important work. IMHRO allows those touched in some way by psychiatric illness to take action and work toward solutions by helping to spur early stage research. IMHRO’s audacious mission to find a cure for psychiatric illness in one generation is what it will take to make meaningful progress, and holds the promise of changing millions of lives around the globe. "
"When I heard of the groundbreaking work the Staglins were doing through their organization IMHRO, such as research into preventing schizophrenia from ever occurring, I hoped to meet them. When I did I was amazed by their non-stop energy and complete devotion to the cause. But most of all, I was moved by their sincere desire to share ideas with people from all backgrounds and fields. As I continue to create films to inspire empathy for those with mental illness, I remain inspired by the Staglins and what IMHRO has done to transform mental health research and improve lives. "
"IMHRO, thank you again for funding CAPPS/ABBRC. Our daughter, Anna, participated in the program 2012-2013 and just received her final assessment. While this research helps others, know how much we appreciated participating with such genuinely dedicated people (very well selected to work with adolescents). It was very helpful for us as well, and provides us with even more hope. We're so impressed with the program."
"From the moment I found IMHRO and met the amazing Staglin family I knew that my advocacy would grow by leaps and bounds. Through their dedication and commitment I found a community of brilliant scientists, passionate philanthropists, music lovers and a new mental health family to call my own. I cherish the work IMHRO does every day to advance the research on brain disorders, to increase the awareness around mental illness and mental health and to create a community of love and support for advocates everywhere. I would not be the person I am today without the inspiration IMHRO has provided me."
"Having struggled with schizophrenia since a young woman, I am deeply grateful for what IMHRO does. IMHRO’s unwavering commitment to support research is an inspiration to those of us who long for the day when a cure for serious mental illness is found. I think of IMHRO as a good friend and kindly mentor who has taken up my cause and fights for my mental health each and every day."
"IMHRO has distinguished itself as a leader in the fight against brain disease. IMHRO’s vision of a world without mental illness seems beyond reach only to those who have not seen firsthand the intensity of IMHRO’s dedication and focus. These folks are not giving up until they’ve won. The Saks Institute is delighted to be IMHRO’s partner in the fight."
"IMHRO is an organization equal parts compassion and science. A critical component of their work is advocacy and voice for millions of people who live with mental illnesses. Equally important is the incredible efforts they provide to further research in learning more about the brain and identifying effective treatments for brain diseases. IMHRO is a leader in the field of mental illness!"
"The support of IMHRO has been absolutely essential to all of the psychosis prediction and prevention efforts of CAPPS and the NAPLS. On behalf of the patients and families who have received high quality clinical services in our program regardless of their ability to pay, and on behalf of the numerous dedicated members of our research and clinical treatment teams, I am so incredibly grateful for IMHRO’s generous contributions. On a personal note, it is very inspiring to see the huge gains made for mental health research and awareness over the past several years, which have been sparked in large part by the efforts of the Staglin family."

Stay Connected

Sign up and receive e-newsletters and more

IMHRO is a 501(c)3 nonprofit, Tax ID # 68-0359707